United Therapeutics (NASDAQ:UTHR – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of $6.24 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the firm posted $4.86 earnings per share. United Therapeutics’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $27 EPS for the next fiscal year.
United Therapeutics Trading Up 1.3 %
NASDAQ UTHR traded up $4.27 during mid-day trading on Tuesday, hitting $339.54. The company’s stock had a trading volume of 160,050 shares, compared to its average volume of 488,941. United Therapeutics has a 52-week low of $208.62 and a 52-week high of $343.98. The stock’s fifty day simple moving average is $304.23 and its two-hundred day simple moving average is $258.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The firm has a market capitalization of $15.06 billion, a P/E ratio of 15.85, a price-to-earnings-growth ratio of 1.47 and a beta of 0.55.
Analyst Ratings Changes
Read Our Latest Stock Analysis on UTHR
Insider Transactions at United Therapeutics
In other news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total value of $929,124.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,551.70. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 100,884 shares of company stock valued at $29,994,539. 12.50% of the stock is currently owned by corporate insiders.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
- Five stocks we like better than United Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- CD Calculator: Certificate of Deposit Calculator
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
- What is a SEC Filing?
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.